Zymeworks 2026 Stifel Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, we're going to go ahead and get started. Thanks to everyone who's stuck around for the last presentation of the day. I am Steve Willey, one of the Senior Biotech Analysts at Stifel, and glad to have with us here to wrap things up Ken Galbraith, who's the CEO of Zymeworks. Ken, any opening statements you want to make before we I know it's been an incredibly busy year for you and your team, and I'm sure seeing Zani getting across the finish line in frontline GEA had to have been the highlight.
Yeah, there's nothing better than working in this business and realizing you've done something that changes the standard of care for a big patient population. By changing, I mean you give a median OS benefit for patients with GEA in the HER2-expressing space, it's eight months by this timeframe, and that's on the median. You realize in some part of the patient population, you're giving them a long-term durable survival benefit. I mean, that's why we do this Yeah this work.
That's really gratifying for us to realize that's something we invented, came up with. It's pretty unique and differentiated. No one else is really doing the same thing, which is the heart of our business to find that. We found a way to develop that in the clinic. We found a way to bring on BeOne as a partner in Asia Pacific, and having the ability to do clinical studies in that indication, specifically in China and rest of Asia, was so important. We wouldn't have got it approved without that. Then bringing on Jazz as a partner in 2022 to provide the additional resources to get us across the finish line and launch, as they're doing now in the U.S.
I mean, all of that was a long 10-year timeframe, and a lot of times in biotech, it doesn't end in that type of positive outcomes. We're pretty encouraged by that, and it makes you want to do it again.
Yeah. I think we're focused.
We celebrated, I think, that day for patients. The next day, we said, "Look, how do we get this feeling again with the innovative R&D we have?" And we have to find a way to turn that into a new medicine somehow to help patients and keep a share of that success for our shareholders to reward them for the risk capital that's put up to make those innovations. Pretty excited. Obviously, at the beginning of the year, we set a pretty aggressive agenda for moving every part of the business in this diversified business model that we have, to showing how improving all the different components that we have available to us can end up in something that's much more valuable at the end of the year. As you saw in our Q3 earnings on Monday, we've done a lot of it.
Yeah. There's still seven weeks left in the year, so there's still time to do the rest of it.
But I think hopefully by the end of the year, and we're sitting early in January, we can talk about all the work we did to move different parts of the business together, which cumulatively together really showed a huge appreciation in value for our shareholders and moved a lot of new medicines closer to where zanidatamab is. Then for 2027 and 2028, we just need to do it all again, do it better, faster, bigger outcomes for us in terms of value, and find the next zanidatamab somewhere in that portfolio that we can work upon.
Pretty excited where we are for this year, but looking forward to where we need to get to over the next two years to really show how this diversified business model can be effective in turning R&D innovation into something that's meaningful for patients and shareholders at the same time.
Okay. Yeah, I know the visibility you've been able to gain into Zani with respect to milestones and royalties has really allowed you to kind of lean into this thing now, right?
I know it is a little bit non-traditional. I know it is a fairly simplistic concept, right? You are going to preserve long-duration cash flows and still do R&D, right? It seems pretty simple. But I know it is kind of against the traditional biotech dogma.
As you have been out, like post-leaning into this, pretty aggressively, how has that messaging process gone with investors?
Yeah, it might be a different pathway than people are used to think about how do you take an R&D innovation and turn that into something valuable for patients and shareholders? We just think there is multiple ways to do that. We made the choice with zanidatamab not to forward integrate to our own sales force, at least in the U.S., to drive that. We felt partnering that would be a better solution for our shareholders in terms of the risk-return profile. We certainly avoided a lot of dilution of capital to get Zani to this position. The share of success we will get from Jazz and BeOne on Zani is pretty fundamental to our shareholders, and pretty interesting from that construct.
I think once you have made that decision, it does open up lots of optionality and flexibility on how do we move interesting R&D forward, that is just not off our balance sheet, unencumbered, hoping we can take it all the way ourselves. I think we have seen lots of situations where that works out, and we have seen lots of situations, probably more, where that does not, or the equity dilution and the risk associated with that, the binary risk associated with some of those studies destroys shareholder value. At this point, we think we have a really good, interesting shareable model based on just our existing partnered programs. If you look at just zanidatamab over its lifetime, hopefully pasritamig has a successful phase III readout in the first prostate cancer phase III next year. That is also an interesting component for us.
We have a commercial product, YUPELRI, that we acquired in the Theravance acquisition that we co-promote with Viatris, which can also add to the top line. We have a really great shareholder model with what we have right now, and what we are trying to do is be additive to that without destroying that value that is in front of us.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
